<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533910</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00006863</org_study_id>
    <nct_id>NCT00533910</nct_id>
  </id_info>
  <brief_title>Rifaximin in Minimal Hepatic Encephalopathy</brief_title>
  <official_title>Effect of Rifaximin on Driving Performance, Psychometric Test Performance and Quality of Life in Cirrhotic Patients With Minimal Hepatic Encephalopathy: Randomized, Double-blind, Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunter Holmes Mcguire Veteran Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hunter Holmes Mcguire Veteran Affairs Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether alteration of gut flora with rifaximin can&#xD;
      lead to improvement in driving performance, psychometric test performance, and quality of&#xD;
      life in patients with minimal hepatic encephalopathy (MHE) and cirrhosis in a randomized,&#xD;
      blinded, placebo-controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Driving Performance</measure>
    <time_frame>8 weeks</time_frame>
    <description>Total driving errors at the end of drug/placebo. Minimum is zero, maximum is not defined. Higher number indicates greater errors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychometric Test Performance</measure>
    <time_frame>8 weeks</time_frame>
    <description>Z score of combined cognitive tests at end of rifaximin/placebo; higher scores indicate better psychometric test performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Sickness Impact Profile Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Total score ranging from 0 through &gt;100 at the end of drug/placebo. Higher score indicates worse QOL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will be given placebo and follow the exact procedures as the experimental section</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>550mg BID rifaximin for 8 weeks</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>same as the experimental arm</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
          -  Cirrhosis diagnosed on clinical grounds&#xD;
&#xD;
          -  MHE diagnosed by abnormalities in a psychometric battery (NCT-A, NCT-B, ICT BDT and&#xD;
             DST impaired beyond 2 standard deviations of known control values on any of the above&#xD;
             3 tests will be considered to have MHE)&#xD;
&#xD;
          -  Current drivers (valid driving license and driving at least 20 miles/week)&#xD;
&#xD;
          -  All women of child-bearing potential will be required to use effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or recent (&lt; 6 month) use of alcohol (AUDIT questionnaire will be used; any&#xD;
             cirrhotic with a value of &gt; 0 will be excluded) and a positive blood alcohol level&#xD;
&#xD;
          -  Use of antibiotics within last 6 weeks&#xD;
&#xD;
          -  Allergy to rifaximin, rifabutin, rifampin, or rifapentine&#xD;
&#xD;
          -  Infection or gastrointestinal hemorrhage within the last 6 weeks&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Hepatocellular carcinoma&#xD;
&#xD;
          -  Psychoactive drug use, including interferon concurrently&#xD;
&#xD;
          -  Non-drivers and those who drive less than 20 miles/week&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Excluding patients with OHE:&#xD;
&#xD;
               -  Detailed neurological examination to check for dysarthria, asterixis, ataxia and&#xD;
                  disorientation&#xD;
&#xD;
               -  Detailed history-taking from friends/relatives only after taking the patient's&#xD;
                  permission&#xD;
&#xD;
               -  Mini-mental status examination &gt; 25&#xD;
&#xD;
               -  Episode of overt (clinical hepatic encephalopathy) within 6 months&#xD;
&#xD;
               -  Current treatment with lactulose, rifaximin, zinc, or metronidazole&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jasmohan S Bajaj, MBBS, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology. 2011 Feb;140(2):478-487.e1. doi: 10.1053/j.gastro.2010.08.061. Epub 2010 Sep 21.</citation>
    <PMID>20849805</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>December 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2020</results_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunter Holmes Mcguire Veteran Affairs Medical Center</investigator_affiliation>
    <investigator_full_name>Jasmohan Bajaj</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Minimal hepatic encephalopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Will be given placebo and follow the exact procedures as the experimental section&#xD;
placebo: same as the experimental arm</description>
        </group>
        <group group_id="P2">
          <title>Rifaximin</title>
          <description>Rifaximin: 550mg BID rifaximin for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Will be given placebo and follow the exact procedures as the experimental section&#xD;
placebo: same as the experimental arm</description>
        </group>
        <group group_id="B2">
          <title>Rifaximin</title>
          <description>Rifaximin: 550mg BID rifaximin for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Driving Performance</title>
        <description>Total driving errors at the end of drug/placebo. Minimum is zero, maximum is not defined. Higher number indicates greater errors.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Will be given placebo and follow the exact procedures as the experimental section&#xD;
placebo: same as the experimental arm</description>
          </group>
          <group group_id="O2">
            <title>Rifaximin</title>
            <description>Rifaximin: 550mg BID rifaximin for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Driving Performance</title>
          <description>Total driving errors at the end of drug/placebo. Minimum is zero, maximum is not defined. Higher number indicates greater errors.</description>
          <units>raw number of driving errors</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="3.9"/>
                    <measurement group_id="O2" value="5.5" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psychometric Test Performance</title>
        <description>Z score of combined cognitive tests at end of rifaximin/placebo; higher scores indicate better psychometric test performance</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Will be given placebo and follow the exact procedures as the experimental section&#xD;
placebo: same as the experimental arm</description>
          </group>
          <group group_id="O2">
            <title>Rifaximin</title>
            <description>Rifaximin: 550mg BID rifaximin for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Psychometric Test Performance</title>
          <description>Z score of combined cognitive tests at end of rifaximin/placebo; higher scores indicate better psychometric test performance</description>
          <units>Z scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.17"/>
                    <measurement group_id="O2" value="1.19" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Sickness Impact Profile Score</title>
        <description>Total score ranging from 0 through &gt;100 at the end of drug/placebo. Higher score indicates worse QOL</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Will be given placebo and follow the exact procedures as the experimental section&#xD;
placebo: same as the experimental arm</description>
          </group>
          <group group_id="O2">
            <title>Rifaximin</title>
            <description>Rifaximin: 550mg BID rifaximin for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sickness Impact Profile Score</title>
          <description>Total score ranging from 0 through &gt;100 at the end of drug/placebo. Higher score indicates worse QOL</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="3"/>
                    <measurement group_id="O2" value="10" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weels</time_frame>
      <desc>Same as the ones in www.clinicaltrials.gov definitions</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Will be given placebo and follow the exact procedures as the experimental section&#xD;
placebo: same as the experimental arm</description>
        </group>
        <group group_id="E2">
          <title>Rifaximin</title>
          <description>Rifaximin: 550mg BID rifaximin for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jasmohan Bajaj</name_or_title>
      <organization>Hunter Holmes McGuire VAMC</organization>
      <phone>804 675 5802</phone>
      <email>jasmohan@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

